Literature DB >> 25625587

Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.

Dimitrios Patsouras1, Kostis Papaxoinis2, Alkiviadis Kostakis3, Michael C Safioleas4, Andreas C Lazaris5, Polyxeni Nicolopoulou-Stamati5.   

Abstract

Fibroblast activation protein (FAP), a selective protein for tumor stromal fibroblasts, is expressed in >90% of human epithelial carcinomas. A characteristic feature of pancreatic cancer is an extensive fibrotic or desmoplastic reaction surrounding the primary tumor. The present study aimed to evaluate the expression levels of FAP and vascular endothelial growth factor (VEGF) and determine their correlation in pancreatic adenocarcinoma. Confocal laser scanning microscopy and conventional immunohistochemical analysis were used to quantify FAP and VEGF expression levels in formalin‑fixed and paraffin‑embedded tissue biopsies from 46 patients (male, 26; female, 20; mean age, 66 years; age range, 53‑80 years) with pancreatic adenocarcinoma stage IIA or IIB. The expression levels of FAP in the neoplastic and adjacent normal tissue were significantly higher in stage IIB patients, compared with stage IIA patients. FAP expression was correlated with positive lymph nodes, resulting in poor prognosis for stage IIB patients. The partial correlation coefficient between FAP and VEGF expression levels was 0.39 (P=0.007), and the two factors had an effect on patient survival. Multivariate analysis demonstrated the prognostic superiority of FAP over VEGF, which is considered to be the most consistently reproducible molecular marker with prognostic value in resected pancreatic adenocarcinoma. Due to the limited beneficial effect of current systemic therapies for pancreatic adenocarcinoma, targeting FAP may be a potential therapeutic strategy and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25625587     DOI: 10.3892/mmr.2015.3259

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

2.  Microvascular density and endothelial area correlate with Ki-67 proliferative index in surgically-treated pancreatic ductal adenocarcinoma patients.

Authors:  Michele Ammendola; Rosario Sacco; Ilaria Marech; Giuseppe Sammarco; Valeria Zuccalà; Maria Luposella; Rosa Patruno; Marcella Giordano; Eustachio Ruggieri; Nicola Zizzo; Cosmo Damiano Gadaleta; Girolamo Ranieri
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

Review 3.  Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.

Authors:  Circe D van der Heide; Simone U Dalm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-05       Impact factor: 9.236

4.  CT radiomics signature: a potential biomarker for fibroblast activation protein expression in patients with pancreatic ductal adenocarcinoma.

Authors:  Yinghao Meng; Jieyu Yu; Mengmeng Zhu; Jian Zhou; Na Li; Fang Liu; Hao Zhang; Xu Fang; Jing Li; Xiaocheng Feng; Li Wang; Hui Jiang; Jianping Lu; Chengwei Shao; Yun Bian
Journal:  Abdom Radiol (NY)       Date:  2022-04-22

5.  Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.

Authors:  M M Koczorowska; S Tholen; F Bucher; L Lutz; J N Kizhakkedathu; O De Wever; U F Wellner; M L Biniossek; A Stahl; S Lassmann; O Schilling
Journal:  Mol Oncol       Date:  2015-08-11       Impact factor: 6.603

6.  Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts.

Authors:  Diana Avery; Priya Govindaraju; Michele Jacob; Leslie Todd; James Monslow; Ellen Puré
Journal:  Matrix Biol       Date:  2017-12-14       Impact factor: 11.583

7.  Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt/ β-catenin pathway.

Authors:  Jiuyang Liu; Chaoqun Huang; Chunwei Peng; Fei Xu; Yan Li; Yonemura Yutaka; Bin Xiong; Xiaojun Yang
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

Review 8.  Fibroblast activation protein-based theranostics in pancreatic cancer.

Authors:  Chien-Shan Cheng; Pei-Wen Yang; Yun Sun; Shao-Li Song; Zhen Chen
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

Review 9.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.

Authors:  Ellen Puré; Rachel Blomberg
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.